Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japanese pharmaceutical company Takeda has begun phase II trials in the US and Europe for TAK-491, its investigational compound for the treatment of hypertension.
Subscribe to our email newsletter
The drug is one of two that Takeda has in development as potential successors to its blockbuster hypertension drug Blopress. The other drug vying to take over from Blopress is TAK-536, also in phase II development.
TAK-491, an angiotensin receptor blocker (ARB), is expected to show stronger anti-hypertensive action compared to existing ARBs on the market.
In the anti-hypertensive market, the ARB class is now recognized as a mainstream treatment option. According to Takeda, TAK-491, if successfully developed and launched, has the potential to become the most effective member of this important class of drugs, and is expected to support the expansion of the company’s US Actos franchise into lifestyle-related diseases.